Profile data is unavailable for this security.
About the company
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
- Revenue in USD (TTM)109.74m
- Net income in USD-2.88bn
- Incorporated2020
- Employees1.37k
- LocationGrail Inc1525 O'brien DriveMENLO PARK 94025United StatesUSA
- Phone+1 (650) 771-9796
- Fax+1 (302) 655-5049
- Websitehttps://www.galleri.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Monte Rosa Therapeutics Inc | 5.76m | -130.41m | 397.70m | 103.00 | -- | 1.77 | -- | 69.06 | -2.24 | -2.24 | 0.0967 | 3.66 | 0.0185 | -- | 1.05 | 43,300.75 | -41.88 | -- | -46.47 | -- | -- | -- | -2,264.53 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 398.06m | 25.00 | -- | -- | -- | 241.98 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
iTeos Therapeutics Inc | 35.00m | -108.14m | 411.24m | 157.00 | -- | 0.6194 | -- | 11.75 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Ginkgo Bioworks Holdings Inc | 184.34m | -897.68m | 421.13m | 1.22k | -- | 4.96 | -- | 2.28 | -18.03 | -18.03 | 3.69 | 1.62 | 0.0941 | -- | 4.20 | 151,342.40 | -45.83 | -- | -50.04 | -- | 80.22 | -- | -486.98 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
Instil Bio Inc | 0.00 | -119.58m | 430.88m | 49.00 | -- | 2.21 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
Grail Inc | 109.74m | -2.88bn | 433.14m | 1.37k | -- | 0.1607 | -- | 3.95 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
Verve Therapeutics Inc | 20.65m | -192.65m | 439.20m | 255.00 | -- | 0.8036 | -- | 21.27 | -2.59 | -2.59 | 0.275 | 6.46 | 0.032 | -- | 8.05 | 80,972.55 | -29.87 | -- | -31.67 | -- | -- | -- | -933.03 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
C4 Therapeutics Inc | 29.38m | -107.87m | 440.29m | 145.00 | -- | 1.77 | -- | 14.99 | -1.90 | -1.90 | 0.4944 | 3.59 | 0.0777 | -- | 26.77 | 202,606.90 | -28.53 | -25.91 | -33.00 | -29.45 | -- | -- | -367.17 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Taysha Gene Therapies Inc | 12.87m | -114.34m | 440.63m | 52.00 | -- | 3.98 | -- | 34.23 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Fate Therapeutics Inc | 12.32m | -175.72m | 440.71m | 181.00 | -- | 1.11 | -- | 35.78 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Larimar Therapeutics Inc | 0.00 | -58.34m | 451.11m | 42.00 | -- | 2.13 | -- | -- | -1.11 | -1.11 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -33.44 | -42.22 | -36.41 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
SAGE Therapeutics Inc | 97.24m | -445.67m | 457.88m | 487.00 | -- | 0.7272 | -- | 4.71 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Prime Medicine Inc | 591.00k | -217.44m | 459.72m | 234.00 | -- | 2.34 | -- | 777.86 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Aura Biosciences Inc | 0.00 | -80.69m | 474.73m | 88.00 | -- | 2.48 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Anavex Life Sciences Corp | 0.00 | -41.53m | 478.25m | 40.00 | -- | 3.69 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
PRIMECAP Management Co.as of 30 Jun 2024 | 1.87m | 6.01% |
Geode Capital Management LLCas of 30 Jun 2024 | 421.77k | 1.36% |
CaaS Capital Management LPas of 30 Jun 2024 | 249.39k | 0.80% |
TIAA-CREF Investment Management LLCas of 30 Jun 2024 | 241.00k | 0.78% |
Newton Investment Management North America LLCas of 30 Jun 2024 | 188.23k | 0.61% |
Teacher Retirement System of Texasas of 30 Jun 2024 | 111.88k | 0.36% |
The Bank of New York Mellon Corp. (Investment Management)as of 30 Jun 2024 | 109.93k | 0.35% |
Swedbank Robur Fonder ABas of 30 Jun 2024 | 92.78k | 0.30% |
Teachers Advisors LLCas of 30 Jun 2024 | 69.51k | 0.22% |
PGGM Vermogensbeheer BVas of 30 Jun 2024 | 68.56k | 0.22% |